Lifeward (LFWD) to Release Quarterly Earnings on Tuesday

Lifeward (NASDAQ:LFWD) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $6.3110 million for the quarter. Lifeward has set its FY 2025 guidance at EPS.Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:30 AM ET.

Lifeward (NASDAQ:LFWD) last posted its earnings results on Thursday, August 14th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.33). Lifeward had a negative net margin of 121.80% and a negative return on equity of 137.91%. The business had revenue of $5.72 million for the quarter, compared to analyst estimates of $6.62 million. On average, analysts expect Lifeward to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lifeward Stock Down 2.0%

Shares of NASDAQ:LFWD traded down $0.01 during trading on Tuesday, reaching $0.57. 99,918 shares of the company’s stock traded hands, compared to its average volume of 1,077,608. Lifeward has a fifty-two week low of $0.50 and a fifty-two week high of $4.00. The firm has a market cap of $8.95 million, a PE ratio of -0.18 and a beta of 0.20. The company has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $0.88.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lifeward in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.